nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—CCR1—connective tissue—skin cancer	0.0148	0.235	CbGeAlD
Raltegravir—CCR1—mammalian vulva—skin cancer	0.0122	0.193	CbGeAlD
Raltegravir—CCR1—lymphoid tissue—skin cancer	0.0108	0.172	CbGeAlD
Raltegravir—CCR1—female reproductive system—skin cancer	0.0104	0.165	CbGeAlD
Raltegravir—CCR1—head—skin cancer	0.00873	0.138	CbGeAlD
Raltegravir—CCR1—Peptide GPCRs—MC1R—skin cancer	0.00816	0.172	CbGpPWpGaD
Raltegravir—CCR1—lymph node—skin cancer	0.00611	0.0968	CbGeAlD
Raltegravir—CCR1—Peptide ligand-binding receptors—MC1R—skin cancer	0.00384	0.0807	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00301	0.0632	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTCH2—skin cancer	0.00271	0.057	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00258	0.0541	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00198	0.0416	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—MC1R—skin cancer	0.00196	0.0412	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00169	0.0356	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RHOU—skin cancer	0.00168	0.0354	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SHH—skin cancer	0.0014	0.0294	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTCH2—skin cancer	0.00139	0.0293	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTCH1—skin cancer	0.00132	0.0278	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SMO—skin cancer	0.00132	0.0278	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTGER4—skin cancer	0.00129	0.0271	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—MC1R—skin cancer	0.00111	0.0233	CbGpPWpGaD
Raltegravir—Asthenia—Vemurafenib—skin cancer	0.00102	0.00115	CcSEcCtD
Raltegravir—Hallucination—Temozolomide—skin cancer	0.00102	0.00114	CcSEcCtD
Raltegravir—Hypoaesthesia—Temozolomide—skin cancer	0.00102	0.00114	CcSEcCtD
Raltegravir—Chills—Dactinomycin—skin cancer	0.00101	0.00114	CcSEcCtD
Raltegravir—Urinary tract disorder—Temozolomide—skin cancer	0.00101	0.00114	CcSEcCtD
Raltegravir—Oedema peripheral—Temozolomide—skin cancer	0.00101	0.00113	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MC1R—skin cancer	0.00101	0.0212	CbGpPWpGaD
Raltegravir—Pruritus—Vemurafenib—skin cancer	0.00101	0.00113	CcSEcCtD
Raltegravir—Connective tissue disorder—Temozolomide—skin cancer	0.00101	0.00113	CcSEcCtD
Raltegravir—Lethargy—Docetaxel—skin cancer	0.001	0.00113	CcSEcCtD
Raltegravir—Urethral disorder—Temozolomide—skin cancer	0.001	0.00113	CcSEcCtD
Raltegravir—Alopecia—Dactinomycin—skin cancer	0.001	0.00112	CcSEcCtD
Raltegravir—Feeling abnormal—Imiquimod—skin cancer	0.001	0.00112	CcSEcCtD
Raltegravir—Gastrointestinal pain—Imiquimod—skin cancer	0.000992	0.00112	CcSEcCtD
Raltegravir—Epistaxis—Fluorouracil—skin cancer	0.00099	0.00111	CcSEcCtD
Raltegravir—Visual impairment—Temozolomide—skin cancer	0.000986	0.00111	CcSEcCtD
Raltegravir—Erythema—Dactinomycin—skin cancer	0.000985	0.00111	CcSEcCtD
Raltegravir—Pain in extremity—Docetaxel—skin cancer	0.000983	0.00111	CcSEcCtD
Raltegravir—Ill-defined disorder—Bleomycin—skin cancer	0.00098	0.0011	CcSEcCtD
Raltegravir—Anaemia—Bleomycin—skin cancer	0.000976	0.0011	CcSEcCtD
Raltegravir—Diarrhoea—Vemurafenib—skin cancer	0.000973	0.00109	CcSEcCtD
Raltegravir—Migraine—Docetaxel—skin cancer	0.000968	0.00109	CcSEcCtD
Raltegravir—Erythema multiforme—Temozolomide—skin cancer	0.000967	0.00109	CcSEcCtD
Raltegravir—Urticaria—Imiquimod—skin cancer	0.000964	0.00108	CcSEcCtD
Raltegravir—Abdominal pain—Imiquimod—skin cancer	0.000959	0.00108	CcSEcCtD
Raltegravir—Body temperature increased—Imiquimod—skin cancer	0.000959	0.00108	CcSEcCtD
Raltegravir—Eye disorder—Temozolomide—skin cancer	0.000956	0.00108	CcSEcCtD
Raltegravir—Tinnitus—Temozolomide—skin cancer	0.000954	0.00107	CcSEcCtD
Raltegravir—Malaise—Bleomycin—skin cancer	0.000952	0.00107	CcSEcCtD
Raltegravir—Cardiac disorder—Temozolomide—skin cancer	0.00095	0.00107	CcSEcCtD
Raltegravir—Dizziness—Vemurafenib—skin cancer	0.00094	0.00106	CcSEcCtD
Raltegravir—Hypoaesthesia—Fluorouracil—skin cancer	0.000938	0.00105	CcSEcCtD
Raltegravir—Angiopathy—Temozolomide—skin cancer	0.000928	0.00104	CcSEcCtD
Raltegravir—Immune system disorder—Temozolomide—skin cancer	0.000924	0.00104	CcSEcCtD
Raltegravir—Mediastinal disorder—Temozolomide—skin cancer	0.000922	0.00104	CcSEcCtD
Raltegravir—Cough—Bleomycin—skin cancer	0.000921	0.00104	CcSEcCtD
Raltegravir—Chills—Temozolomide—skin cancer	0.000918	0.00103	CcSEcCtD
Raltegravir—Ill-defined disorder—Dactinomycin—skin cancer	0.000914	0.00103	CcSEcCtD
Raltegravir—Anaemia—Dactinomycin—skin cancer	0.00091	0.00102	CcSEcCtD
Raltegravir—Vomiting—Vemurafenib—skin cancer	0.000904	0.00102	CcSEcCtD
Raltegravir—Alopecia—Temozolomide—skin cancer	0.000904	0.00102	CcSEcCtD
Raltegravir—Dry skin—Docetaxel—skin cancer	0.000901	0.00101	CcSEcCtD
Raltegravir—Chest pain—Bleomycin—skin cancer	0.000899	0.00101	CcSEcCtD
Raltegravir—Myalgia—Bleomycin—skin cancer	0.000899	0.00101	CcSEcCtD
Raltegravir—Abdominal pain upper—Docetaxel—skin cancer	0.000898	0.00101	CcSEcCtD
Raltegravir—Rash—Vemurafenib—skin cancer	0.000897	0.00101	CcSEcCtD
Raltegravir—Mental disorder—Temozolomide—skin cancer	0.000896	0.00101	CcSEcCtD
Raltegravir—Dermatitis—Vemurafenib—skin cancer	0.000896	0.00101	CcSEcCtD
Raltegravir—Hypersensitivity—Imiquimod—skin cancer	0.000894	0.001	CcSEcCtD
Raltegravir—Headache—Vemurafenib—skin cancer	0.000891	0.001	CcSEcCtD
Raltegravir—Malnutrition—Temozolomide—skin cancer	0.000891	0.001	CcSEcCtD
Raltegravir—Erythema—Temozolomide—skin cancer	0.000891	0.001	CcSEcCtD
Raltegravir—Breast disorder—Docetaxel—skin cancer	0.000889	0.000999	CcSEcCtD
Raltegravir—Discomfort—Bleomycin—skin cancer	0.000888	0.000999	CcSEcCtD
Raltegravir—Malaise—Dactinomycin—skin cancer	0.000888	0.000999	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000886	0.000996	CcSEcCtD
Raltegravir—Nasopharyngitis—Docetaxel—skin cancer	0.000879	0.000989	CcSEcCtD
Raltegravir—Dysgeusia—Temozolomide—skin cancer	0.000872	0.000981	CcSEcCtD
Raltegravir—Asthenia—Imiquimod—skin cancer	0.00087	0.000979	CcSEcCtD
Raltegravir—Confusional state—Bleomycin—skin cancer	0.000869	0.000977	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000867	0.000975	CcSEcCtD
Raltegravir—Back pain—Temozolomide—skin cancer	0.000861	0.000969	CcSEcCtD
Raltegravir—Pruritus—Imiquimod—skin cancer	0.000858	0.000965	CcSEcCtD
Raltegravir—Infection—Bleomycin—skin cancer	0.000856	0.000963	CcSEcCtD
Raltegravir—Nausea—Vemurafenib—skin cancer	0.000845	0.00095	CcSEcCtD
Raltegravir—Thrombocytopenia—Bleomycin—skin cancer	0.000844	0.000949	CcSEcCtD
Raltegravir—Myalgia—Dactinomycin—skin cancer	0.000838	0.000943	CcSEcCtD
Raltegravir—Tremor—Temozolomide—skin cancer	0.000834	0.000938	CcSEcCtD
Raltegravir—Alopecia—Fluorouracil—skin cancer	0.000833	0.000937	CcSEcCtD
Raltegravir—Diarrhoea—Imiquimod—skin cancer	0.00083	0.000933	CcSEcCtD
Raltegravir—Discomfort—Dactinomycin—skin cancer	0.000828	0.000931	CcSEcCtD
Raltegravir—Ill-defined disorder—Temozolomide—skin cancer	0.000826	0.000929	CcSEcCtD
Raltegravir—Anaemia—Temozolomide—skin cancer	0.000823	0.000926	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTCH2—skin cancer	0.000822	0.0173	CbGpPWpGaD
Raltegravir—Erythema—Fluorouracil—skin cancer	0.000821	0.000923	CcSEcCtD
Raltegravir—Agitation—Temozolomide—skin cancer	0.000818	0.00092	CcSEcCtD
Raltegravir—Malaise—Temozolomide—skin cancer	0.000803	0.000903	CcSEcCtD
Raltegravir—Dizziness—Imiquimod—skin cancer	0.000802	0.000902	CcSEcCtD
Raltegravir—Vertigo—Temozolomide—skin cancer	0.0008	0.0009	CcSEcCtD
Raltegravir—Infection—Dactinomycin—skin cancer	0.000798	0.000898	CcSEcCtD
Raltegravir—Neutropenia—Docetaxel—skin cancer	0.000795	0.000894	CcSEcCtD
Raltegravir—Palpitations—Temozolomide—skin cancer	0.000787	0.000885	CcSEcCtD
Raltegravir—Thrombocytopenia—Dactinomycin—skin cancer	0.000787	0.000885	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000785	0.000883	CcSEcCtD
Raltegravir—Cough—Temozolomide—skin cancer	0.000777	0.000874	CcSEcCtD
Raltegravir—Paraesthesia—Bleomycin—skin cancer	0.000774	0.00087	CcSEcCtD
Raltegravir—Weight increased—Docetaxel—skin cancer	0.000774	0.00087	CcSEcCtD
Raltegravir—Vomiting—Imiquimod—skin cancer	0.000771	0.000867	CcSEcCtD
Raltegravir—Weight decreased—Docetaxel—skin cancer	0.000769	0.000865	CcSEcCtD
Raltegravir—Hypertension—Temozolomide—skin cancer	0.000769	0.000865	CcSEcCtD
Raltegravir—Rash—Imiquimod—skin cancer	0.000765	0.00086	CcSEcCtD
Raltegravir—Dermatitis—Imiquimod—skin cancer	0.000764	0.000859	CcSEcCtD
Raltegravir—Headache—Imiquimod—skin cancer	0.00076	0.000854	CcSEcCtD
Raltegravir—Anaemia—Fluorouracil—skin cancer	0.000758	0.000853	CcSEcCtD
Raltegravir—Arthralgia—Temozolomide—skin cancer	0.000758	0.000853	CcSEcCtD
Raltegravir—Myalgia—Temozolomide—skin cancer	0.000758	0.000853	CcSEcCtD
Raltegravir—Infestation—Docetaxel—skin cancer	0.000758	0.000852	CcSEcCtD
Raltegravir—Infestation NOS—Docetaxel—skin cancer	0.000758	0.000852	CcSEcCtD
Raltegravir—Anxiety—Temozolomide—skin cancer	0.000756	0.00085	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000753	0.000847	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000751	0.000845	CcSEcCtD
Raltegravir—Discomfort—Temozolomide—skin cancer	0.000749	0.000842	CcSEcCtD
Raltegravir—Decreased appetite—Bleomycin—skin cancer	0.000749	0.000842	CcSEcCtD
Raltegravir—Acute coronary syndrome—Docetaxel—skin cancer	0.000747	0.00084	CcSEcCtD
Raltegravir—Renal failure—Docetaxel—skin cancer	0.000745	0.000838	CcSEcCtD
Raltegravir—Neuropathy peripheral—Docetaxel—skin cancer	0.000743	0.000835	CcSEcCtD
Raltegravir—Myocardial infarction—Docetaxel—skin cancer	0.000743	0.000835	CcSEcCtD
Raltegravir—Dry mouth—Temozolomide—skin cancer	0.000742	0.000834	CcSEcCtD
Raltegravir—Pain—Bleomycin—skin cancer	0.000737	0.000829	CcSEcCtD
Raltegravir—Confusional state—Temozolomide—skin cancer	0.000733	0.000824	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000732	0.000823	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PTGER4—skin cancer	0.000729	0.0153	CbGpPWpGaD
Raltegravir—Infection—Temozolomide—skin cancer	0.000722	0.000812	CcSEcCtD
Raltegravir—Nausea—Imiquimod—skin cancer	0.00072	0.00081	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—SHH—skin cancer	0.000717	0.0151	CbGpPWpGaD
Raltegravir—Hepatobiliary disease—Docetaxel—skin cancer	0.000717	0.000806	CcSEcCtD
Raltegravir—Epistaxis—Docetaxel—skin cancer	0.000715	0.000804	CcSEcCtD
Raltegravir—Nervous system disorder—Temozolomide—skin cancer	0.000713	0.000802	CcSEcCtD
Raltegravir—Thrombocytopenia—Temozolomide—skin cancer	0.000712	0.0008	CcSEcCtD
Raltegravir—Feeling abnormal—Bleomycin—skin cancer	0.00071	0.000798	CcSEcCtD
Raltegravir—Skin disorder—Temozolomide—skin cancer	0.000706	0.000794	CcSEcCtD
Raltegravir—Hyperhidrosis—Temozolomide—skin cancer	0.000703	0.00079	CcSEcCtD
Raltegravir—Chest pain—Fluorouracil—skin cancer	0.000699	0.000786	CcSEcCtD
Raltegravir—Myalgia—Fluorouracil—skin cancer	0.000699	0.000786	CcSEcCtD
Raltegravir—Decreased appetite—Dactinomycin—skin cancer	0.000699	0.000786	CcSEcCtD
Raltegravir—Fatigue—Dactinomycin—skin cancer	0.000693	0.000779	CcSEcCtD
Raltegravir—Discomfort—Fluorouracil—skin cancer	0.00069	0.000776	CcSEcCtD
Raltegravir—Pain—Dactinomycin—skin cancer	0.000687	0.000773	CcSEcCtD
Raltegravir—Urticaria—Bleomycin—skin cancer	0.000685	0.00077	CcSEcCtD
Raltegravir—Body temperature increased—Bleomycin—skin cancer	0.000681	0.000766	CcSEcCtD
Raltegravir—Hepatitis—Docetaxel—skin cancer	0.00068	0.000765	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PTCH1—skin cancer	0.00068	0.0143	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SMO—skin cancer	0.00068	0.0143	CbGpPWpGaD
Raltegravir—Hypoaesthesia—Docetaxel—skin cancer	0.000677	0.000761	CcSEcCtD
Raltegravir—Confusional state—Fluorouracil—skin cancer	0.000675	0.000759	CcSEcCtD
Raltegravir—Urinary tract disorder—Docetaxel—skin cancer	0.000672	0.000756	CcSEcCtD
Raltegravir—Oedema peripheral—Docetaxel—skin cancer	0.00067	0.000754	CcSEcCtD
Raltegravir—Connective tissue disorder—Docetaxel—skin cancer	0.000669	0.000752	CcSEcCtD
Raltegravir—Urethral disorder—Docetaxel—skin cancer	0.000667	0.00075	CcSEcCtD
Raltegravir—Infection—Fluorouracil—skin cancer	0.000665	0.000748	CcSEcCtD
Raltegravir—Feeling abnormal—Dactinomycin—skin cancer	0.000662	0.000745	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000662	0.000745	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PTGER4—skin cancer	0.000662	0.0139	CbGpPWpGaD
Raltegravir—Insomnia—Temozolomide—skin cancer	0.000657	0.000739	CcSEcCtD
Raltegravir—Gastrointestinal pain—Dactinomycin—skin cancer	0.000657	0.000739	CcSEcCtD
Raltegravir—Nervous system disorder—Fluorouracil—skin cancer	0.000657	0.000739	CcSEcCtD
Raltegravir—Thrombocytopenia—Fluorouracil—skin cancer	0.000656	0.000737	CcSEcCtD
Raltegravir—Visual impairment—Docetaxel—skin cancer	0.000656	0.000737	CcSEcCtD
Raltegravir—Paraesthesia—Temozolomide—skin cancer	0.000653	0.000734	CcSEcCtD
Raltegravir—Somnolence—Temozolomide—skin cancer	0.000646	0.000727	CcSEcCtD
Raltegravir—Erythema multiforme—Docetaxel—skin cancer	0.000643	0.000723	CcSEcCtD
Raltegravir—Dyspepsia—Temozolomide—skin cancer	0.00064	0.000719	CcSEcCtD
Raltegravir—Eye disorder—Docetaxel—skin cancer	0.000636	0.000715	CcSEcCtD
Raltegravir—Abdominal pain—Dactinomycin—skin cancer	0.000635	0.000714	CcSEcCtD
Raltegravir—Body temperature increased—Dactinomycin—skin cancer	0.000635	0.000714	CcSEcCtD
Raltegravir—Hypersensitivity—Bleomycin—skin cancer	0.000635	0.000714	CcSEcCtD
Raltegravir—Decreased appetite—Temozolomide—skin cancer	0.000632	0.000711	CcSEcCtD
Raltegravir—Cardiac disorder—Docetaxel—skin cancer	0.000631	0.00071	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Temozolomide—skin cancer	0.000628	0.000706	CcSEcCtD
Raltegravir—Fatigue—Temozolomide—skin cancer	0.000627	0.000705	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GLI2—skin cancer	0.000623	0.0131	CbGpPWpGaD
Raltegravir—Pain—Temozolomide—skin cancer	0.000622	0.000699	CcSEcCtD
Raltegravir—Constipation—Temozolomide—skin cancer	0.000622	0.000699	CcSEcCtD
Raltegravir—Asthenia—Bleomycin—skin cancer	0.000618	0.000695	CcSEcCtD
Raltegravir—Angiopathy—Docetaxel—skin cancer	0.000617	0.000694	CcSEcCtD
Raltegravir—Immune system disorder—Docetaxel—skin cancer	0.000615	0.000691	CcSEcCtD
Raltegravir—Mediastinal disorder—Docetaxel—skin cancer	0.000613	0.00069	CcSEcCtD
Raltegravir—Chills—Docetaxel—skin cancer	0.00061	0.000686	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00061	0.000686	CcSEcCtD
Raltegravir—Pruritus—Bleomycin—skin cancer	0.00061	0.000686	CcSEcCtD
Raltegravir—Insomnia—Fluorouracil—skin cancer	0.000606	0.000681	CcSEcCtD
Raltegravir—Paraesthesia—Fluorouracil—skin cancer	0.000601	0.000676	CcSEcCtD
Raltegravir—Alopecia—Docetaxel—skin cancer	0.000601	0.000676	CcSEcCtD
Raltegravir—Feeling abnormal—Temozolomide—skin cancer	0.000599	0.000674	CcSEcCtD
Raltegravir—Mental disorder—Docetaxel—skin cancer	0.000596	0.00067	CcSEcCtD
Raltegravir—Somnolence—Fluorouracil—skin cancer	0.000595	0.00067	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MC1R—skin cancer	0.000595	0.0125	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Temozolomide—skin cancer	0.000594	0.000668	CcSEcCtD
Raltegravir—Erythema—Docetaxel—skin cancer	0.000592	0.000666	CcSEcCtD
Raltegravir—Malnutrition—Docetaxel—skin cancer	0.000592	0.000666	CcSEcCtD
Raltegravir—Hypersensitivity—Dactinomycin—skin cancer	0.000592	0.000666	CcSEcCtD
Raltegravir—Dyspepsia—Fluorouracil—skin cancer	0.00059	0.000663	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GLI1—skin cancer	0.000586	0.0123	CbGpPWpGaD
Raltegravir—Decreased appetite—Fluorouracil—skin cancer	0.000582	0.000655	CcSEcCtD
Raltegravir—Dysgeusia—Docetaxel—skin cancer	0.00058	0.000652	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000578	0.00065	CcSEcCtD
Raltegravir—Urticaria—Temozolomide—skin cancer	0.000577	0.000649	CcSEcCtD
Raltegravir—Asthenia—Dactinomycin—skin cancer	0.000577	0.000648	CcSEcCtD
Raltegravir—Abdominal pain—Temozolomide—skin cancer	0.000575	0.000646	CcSEcCtD
Raltegravir—Body temperature increased—Temozolomide—skin cancer	0.000575	0.000646	CcSEcCtD
Raltegravir—Back pain—Docetaxel—skin cancer	0.000573	0.000644	CcSEcCtD
Raltegravir—Pain—Fluorouracil—skin cancer	0.000573	0.000644	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SUFU—skin cancer	0.000555	0.0117	CbGpPWpGaD
Raltegravir—Feeling abnormal—Fluorouracil—skin cancer	0.000552	0.000621	CcSEcCtD
Raltegravir—Diarrhoea—Dactinomycin—skin cancer	0.00055	0.000618	CcSEcCtD
Raltegravir—Vomiting—Bleomycin—skin cancer	0.000548	0.000616	CcSEcCtD
Raltegravir—Anaemia—Docetaxel—skin cancer	0.000547	0.000616	CcSEcCtD
Raltegravir—Rash—Bleomycin—skin cancer	0.000543	0.000611	CcSEcCtD
Raltegravir—Dermatitis—Bleomycin—skin cancer	0.000543	0.00061	CcSEcCtD
Raltegravir—Hypersensitivity—Temozolomide—skin cancer	0.000536	0.000602	CcSEcCtD
Raltegravir—Urticaria—Fluorouracil—skin cancer	0.000532	0.000598	CcSEcCtD
Raltegravir—Body temperature increased—Fluorouracil—skin cancer	0.000529	0.000595	CcSEcCtD
Raltegravir—Palpitations—Docetaxel—skin cancer	0.000523	0.000589	CcSEcCtD
Raltegravir—Asthenia—Temozolomide—skin cancer	0.000522	0.000586	CcSEcCtD
Raltegravir—Cough—Docetaxel—skin cancer	0.000517	0.000581	CcSEcCtD
Raltegravir—Pruritus—Temozolomide—skin cancer	0.000514	0.000578	CcSEcCtD
Raltegravir—Nausea—Bleomycin—skin cancer	0.000512	0.000576	CcSEcCtD
Raltegravir—Hypertension—Docetaxel—skin cancer	0.000511	0.000575	CcSEcCtD
Raltegravir—Vomiting—Dactinomycin—skin cancer	0.000511	0.000575	CcSEcCtD
Raltegravir—Rash—Dactinomycin—skin cancer	0.000507	0.00057	CcSEcCtD
Raltegravir—Chest pain—Docetaxel—skin cancer	0.000504	0.000567	CcSEcCtD
Raltegravir—Arthralgia—Docetaxel—skin cancer	0.000504	0.000567	CcSEcCtD
Raltegravir—Myalgia—Docetaxel—skin cancer	0.000504	0.000567	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000501	0.000563	CcSEcCtD
Raltegravir—Diarrhoea—Temozolomide—skin cancer	0.000497	0.000559	CcSEcCtD
Raltegravir—Hypersensitivity—Fluorouracil—skin cancer	0.000493	0.000555	CcSEcCtD
Raltegravir—Dry mouth—Docetaxel—skin cancer	0.000493	0.000555	CcSEcCtD
Raltegravir—Confusional state—Docetaxel—skin cancer	0.000487	0.000548	CcSEcCtD
Raltegravir—Dizziness—Temozolomide—skin cancer	0.000481	0.00054	CcSEcCtD
Raltegravir—Infection—Docetaxel—skin cancer	0.00048	0.00054	CcSEcCtD
Raltegravir—Nausea—Dactinomycin—skin cancer	0.000477	0.000537	CcSEcCtD
Raltegravir—Nervous system disorder—Docetaxel—skin cancer	0.000474	0.000533	CcSEcCtD
Raltegravir—Pruritus—Fluorouracil—skin cancer	0.000474	0.000533	CcSEcCtD
Raltegravir—Thrombocytopenia—Docetaxel—skin cancer	0.000473	0.000532	CcSEcCtD
Raltegravir—Skin disorder—Docetaxel—skin cancer	0.00047	0.000528	CcSEcCtD
Raltegravir—Vomiting—Temozolomide—skin cancer	0.000462	0.00052	CcSEcCtD
Raltegravir—Rash—Temozolomide—skin cancer	0.000458	0.000515	CcSEcCtD
Raltegravir—Diarrhoea—Fluorouracil—skin cancer	0.000458	0.000515	CcSEcCtD
Raltegravir—Dermatitis—Temozolomide—skin cancer	0.000458	0.000515	CcSEcCtD
Raltegravir—Headache—Temozolomide—skin cancer	0.000455	0.000512	CcSEcCtD
Raltegravir—Dizziness—Fluorouracil—skin cancer	0.000443	0.000498	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00044	0.000495	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—skin cancer	0.000437	0.000492	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—skin cancer	0.000434	0.000488	CcSEcCtD
Raltegravir—Nausea—Temozolomide—skin cancer	0.000432	0.000485	CcSEcCtD
Raltegravir—Somnolence—Docetaxel—skin cancer	0.00043	0.000483	CcSEcCtD
Raltegravir—Vomiting—Fluorouracil—skin cancer	0.000426	0.000479	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—skin cancer	0.000425	0.000478	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SHH—skin cancer	0.000424	0.00891	CbGpPWpGaD
Raltegravir—Rash—Fluorouracil—skin cancer	0.000422	0.000475	CcSEcCtD
Raltegravir—Dermatitis—Fluorouracil—skin cancer	0.000422	0.000474	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—RASA1—skin cancer	0.000421	0.00885	CbGpPWpGaD
Raltegravir—Decreased appetite—Docetaxel—skin cancer	0.00042	0.000473	CcSEcCtD
Raltegravir—Headache—Fluorouracil—skin cancer	0.00042	0.000472	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—skin cancer	0.000417	0.000469	CcSEcCtD
Raltegravir—Fatigue—Docetaxel—skin cancer	0.000417	0.000469	CcSEcCtD
Raltegravir—Pain—Docetaxel—skin cancer	0.000413	0.000465	CcSEcCtD
Raltegravir—Constipation—Docetaxel—skin cancer	0.000413	0.000465	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SMO—skin cancer	0.000402	0.00844	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTCH1—skin cancer	0.000402	0.00844	CbGpPWpGaD
Raltegravir—Feeling abnormal—Docetaxel—skin cancer	0.000398	0.000448	CcSEcCtD
Raltegravir—Nausea—Fluorouracil—skin cancer	0.000398	0.000447	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—skin cancer	0.000395	0.000444	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTGER4—skin cancer	0.000391	0.00822	CbGpPWpGaD
Raltegravir—Abdominal pain—Docetaxel—skin cancer	0.000382	0.00043	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—skin cancer	0.000382	0.00043	CcSEcCtD
Raltegravir—Hypersensitivity—Docetaxel—skin cancer	0.000356	0.0004	CcSEcCtD
Raltegravir—Asthenia—Docetaxel—skin cancer	0.000347	0.00039	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FOXO4—skin cancer	0.000345	0.00726	CbGpPWpGaD
Raltegravir—Pruritus—Docetaxel—skin cancer	0.000342	0.000385	CcSEcCtD
Raltegravir—Diarrhoea—Docetaxel—skin cancer	0.000331	0.000372	CcSEcCtD
Raltegravir—Dizziness—Docetaxel—skin cancer	0.00032	0.000359	CcSEcCtD
Raltegravir—Vomiting—Docetaxel—skin cancer	0.000307	0.000346	CcSEcCtD
Raltegravir—Rash—Docetaxel—skin cancer	0.000305	0.000343	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—skin cancer	0.000304	0.000342	CcSEcCtD
Raltegravir—Headache—Docetaxel—skin cancer	0.000303	0.000341	CcSEcCtD
Raltegravir—Nausea—Docetaxel—skin cancer	0.000287	0.000323	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TERT—skin cancer	0.000231	0.00485	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NRAS—skin cancer	0.000194	0.00409	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLIN2—skin cancer	0.000193	0.00405	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—skin cancer	0.000183	0.00384	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—skin cancer	0.000167	0.00352	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CSPG4—skin cancer	0.000155	0.00327	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRAS—skin cancer	0.000142	0.00299	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—skin cancer	0.000136	0.00286	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—skin cancer	0.000115	0.00241	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ENO2—skin cancer	0.000106	0.00222	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—skin cancer	9.88e-05	0.00208	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—skin cancer	8.78e-05	0.00185	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—skin cancer	8.4e-05	0.00177	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—skin cancer	8.04e-05	0.00169	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—skin cancer	6.13e-05	0.00129	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—skin cancer	3.68e-05	0.000773	CbGpPWpGaD
